Dr Simon Kerry, CEO of Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, will be attending and presenting at Biotech Showcase 2015, 12-14 January 2015 in San Francisco.
Design and Development of Novel, Highly-Selective HDAC6 Inhibitors for the Treatment of Cancer.
Cecil A., Rogers H., Bone E., Colman L., Finan P., Haque K., Lensun L., Roitt R., Silva F., Ward P., Whale A., Shuttleworth S.
NCRI Meeting, Liverpool, UK, November 3, 2014, A114.
Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/d Inhibitors for the Treatment of Cancer.
Cecil A., Rogers H., Bone E., Colman L., Finan P., Haque K., Lensun L., Roitt S., Silva F., Ward P., Whale A. Shuttleworth S.
NCRI Meeting, Liverpool, UK, November 3, 2014, A143.
2-5 Nov 2014
NCRI, Liverpool, UK
Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory diseases and cancer, today announced that it has further strengthened its R&D team with two new appointments; Dr Simon Roitt, who joins as Head of Clinical Development and Dr Peter Finan, who has been appointed as Karus’s Head of Biology.
7 Oct 2014
UK Bioscience Forum, London, UK
30 Sep-01 Oct 2014
SACHS Biotech in Europe Forum, Basel, Switzerland
Stephen Shuttleworth, CSO of Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, will be attending and presenting two posters at the 10th NCRI Cancer Conference, 2-5 November 2014 in Liverpool.
Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, has announced that Simon Kerry, CEO, will be presenting at the SACHS Biotech in Europe Forum, 30 September – 01 October, 2014 in Basel, Switzerland.
19 June 2014
European MediScience Awards Dinner, London, UK
Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, was featured in the cover story of SciBX, ‘Chromatin’s rising tide’.
12-14 May 2014
BioTrinity 2014, London, UK
5-9 April 2014
AACR, San Diego, USA
Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/δ Inhibitors for the Treatment of Cancer.
Shuttleworth S.J., Bone E.A., Cecil A.R.L., Colman L., Fulton R., Haque K., Hill T.J., McGovern Y., Nodes W.J., Rogers H., Silva F.A., Whale A.D.
Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr LB-7.
Design and Development of a Novel Series of HDAC6-Selective Inhibitors for the Treatment of Cancer.
Shuttleworth S.J., Bone E.A; Cecil A.R.L., Colman L., Fulton R., Hill T.J., McCormick S., Nodes W.J., Rogers H., Silva F.A., Tomassi C.D., Whale A.D.
Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr LB-8.
Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, has announced that it will be giving two poster presentations at the AACR Annual Meeting in San Diego, 5-9th April 2014.
Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, has been featured in the British Private Equity and Venture Capital Association (BVCA)’s handbook of venture capital innovation, Britain’s Hot Talent.
13-16 Jan 2014
Biotech Showcase and J.P. Morgan 32nd Annual Healthcare Conference, San Francisco, USA
Karus Therapeutics Limited
Genesis Building
Library Avenue
Harwell Campus
Oxfordshire OX11 0SG
Tel + 44 (0)1235 829140
Fax + 44 (0)1235 420517
E info@karustherapeutics.com
Registered in England & Wales No 05490954
VAT No 871 4126 33
© 2017 Karus Therapeutics
All Rights Reserved.
